earnings
confidence high
sentiment neutral
materiality 0.75
Adagio Medical Q1 net loss $7.7M; FDA breakthrough device designation
Adagio Medical Holdings, Inc.
2025-Q1 EPS reported
-$0.51
- Net loss of $7.7M ($0.50 per share) vs $8.0M ($10.28 per share) in Q1 2024.
- Cash and cash equivalents $13.0M as of March 31, 2025.
- FDA granted Breakthrough Device Designation for vCLAS Cryoablation System for ventricular tachycardia.
- FULCRUM-VT pivotal study surpassed 50% enrollment; completion on track for H2 2025.
- Hired Deborah Kaster as Chief Business Officer; corporate prioritization on FULCRUM-VT trial.